Unlocking markets for new innovative solutions in medical diagnostics
Bringing cutting-edge solutions to market through an integrated manufacturing and distribution platform, with global reach
Market: Nordic Growth Market
Currency: SEK
Stock ticker: LEVBIO
ISIN: SE0000885501
Level Bio brings cutting-edge solutions to market through an integrated manufacturing and distribution platform. Acting as the bridge between manufacturing and business development, supporting both academic and industry customers and partners in making sure necessary products come to life.
Level Bio is the parent company in the group, with operations in its subsidiaries CyberGene and Techtum Lab. CyberGene develops and manufactures diagnostic kits for the clinical market. Techtum Lab is a distributor and full service partner to molecular biology labs in the Nordics.
The financial reports and investor relations communication is in Swedish
23 april 2026
20 may 2026
20 aug 2026
22 okt 2026
18 feb 2027
Documents from the latest Annual General Meetings
Kallelse årsstämma 2025
Fullmaktsformulär 2025
Kallelse extra bolagsstämma
Förslag till beslut om incitamentsprogram
Bilaga A optionsvillkor
Aktieägarförslag till beslut om riktad emission
Styrelsens redogörelse 13.6
Styrelsens redogörelse 14.8
Revisorsyttrande incitamentsprogram
Revisorsyttrande riktad emission
Fullmaktsformulär EBS 2024
Chairman of the board
More than 25 years of experience in senior positions within Life Science, focusing on diagnostics and laboratories. Former CEO of Abigo, Addlife Development, Addtech Lifescience, BioMerieux, and Organon.
Board member
Professor of chemistry and entrepreneur in molecular diagnostics. 20 years of experience in Life Sciences and co-founder of Tataa-Biocenter. Currently, Mikael is the chairman of the board at MultiD Analyses, SiMSen Diagnostics, and Nygen Analytics
Board member
Worked as CFO at AlphaHelix (now Level Bio) since 2012, and member of the board since 2016. Operationally active in the subsidiary Techtum Lab since 1989.
Board member
Former CEO at AlphaHelix (now Level Bio), where he has been employed since 1986. Previously a product specialist at GlaxoSmithKline.
Board member
Board member since 2020 and currently serves as Vice President of Commercial Excellence at Vitrolife Group, a global leader in medical technology products for IVF. Previous experience includes several international roles at Thermo Fisher.
Board member
Professional investor and entrepreneur. Has been a board member since 2023 and also serves on the board of Nordic Propeye.
CEO
M.Sc. in Forensic Genetics. Former experience includes serving as Global Product Manager at CareDx. Initially started at the subsidiary CyberGene and is currently the CEO of Level Bio
CFO
Has worked as the CFO at Techtum Lab AB since 2012. Board member at AlphaHelix (now Level Bio) since 2004."
"*" indicates required fields
| Name | Number of shares | Capital % |
| Labkompaniet i Sverige AB | 19 873 619 | 29,06 |
| Tobias Schön | 4 687 641 | 6,85 |
| Active Healthtech Nordic AB | 3 478 936 | 5,09 |
| Jörgen Henriksen | 3 474 900 | 5,08 |
| Avanza Pension | 2 962 342 | 4,33 |
| Bengt Koltman | 2 682 021 | 3,92 |
| TTA-LG HoldCo AB | 1 917 136 | 2,80 |
| Anders Reisch | 1 507 927 | 2,20 |
| Ulrica Karlsson | 1 428 571 | 2,09 |
| Stig-Olof Svantesson | 1 346 415 | 1,97 |
CEO
